Today we are officially launching a new consumer tool to join other leading Drugs.com apps – the Drugs.com Medication Guide. Patients and caregivers will have instant access to their most recent personal medication records, the latest advice on drug therapy and medical conditions, and breaking health news tailored to their needs. In addition, consumers can […]
Q4 2012 Drug Sales Data Released: Abilify Overtakes Nexium as the Top Drug by Sales
The latest U.S. drug sales data have been released by Drugs.com. At the close of 2012, Otsuka’s antipsychotic Abilify overtakes AstraZeneca’s acid reducer Nexium and moves into the number one spot with over $1.47 billion in quarterly sales. Sales expanded for all five front-runners over the quarter, although none reached double-digit growth. There are no […]
Drugs.com Pill Reminder featured on Fox Television Orlando
Our popular Pill Reminder app was featured on WOFL Fox 35 Orlando recently. Here’s what they had to say… “People need to take a medicine to keep that blood pressure down and it’s hard to motivate them,” said Dr. Timothy Hendrix of Centra Care. “It’s hard to remind them to take that everyday if they’re […]
Transparency in Clinical Trials: A New Paradigm Shift?
The British Medical Journal (BMJ), a leading, peer-reviewed medical journal, has announced that beginning in January 2013 it will require all authors of drug or device clinical trials who publish in BMJ – whether industry-funded or not – to provide detailed scientific study data to anyone with a reasonable request. Although the policy specifics are […]
Q3 2012 Drug Sales Data Released: Nexium and Abilify Remain the Leading Brands
The latest U.S. drug sales data has been released by Drugs.com. As in the previous quarter, proton-pump inhibitors, antipsychotics and statins remain in the top-selling therapeutic categories. Merck’s asthma and allergy preventive Singulair predictably drops out of the top five drugs due to Q3 patent loss. AstraZeneca’s Nexium, not forecast to lose patent protection until May 2014, […]
Bristol-Myers Squibb Acquisition Results in $1.8 Billion Loss
Bristol-Myers Squibb (BMS) has announced that they will discontinue all development of their chronic hepatitis C (HCV) treatment BMS-986094, a nucleotide polymerase (NS5B) inhibitor previously in Phase 2 clinical trials. BMS reports that nine study patients were hospitalized with heart and kidney toxicity, with one patient death due to heart failure. The exact cause of […]
Q2 2012 Drug Sales Data Released: Loss of Patent Protection Has Significant Effect
The latest U.S. drug sales data has been released by Drugs.com. Proton-pump inhibitors, antipsychotics, asthma therapeutics and statins remain the top selling categories. Plavix and Seroquel dipped in the second quarter due to loss of patent protection. Other top brands such as Singulair, Actos and Diovan are also due to be impacted by year’s end. […]
New Drugs.com Stats Center Shows Top 100 U.S. Drug Sales Data
We are pleased to announce our new interactive stats center featuring quarterly sales data for the top 100 prescribed medicines by U.S. National Sales. Users can view charts showing the sales and unit data for the top 5 drugs plus granular data for the top 100, with graphs and links to other useful resources. This […]
Introducing the new Drugs.com Pill Reminder App for iPhone and iPod Touch
Drugs.com is proud to announce the release of a flexible and easy-to-use Pill Reminder and Personal Medication Record (PMR) app for your iPhone or iPod touch. Use this application to manage any combination of medications, vitamins/supplements and birth control pills. The intuitive interface lets you build a list of medications and setup reminders with ease […]
Drugs.com Pill Identifier Lite mobile app is now the #1 paid medical application in the Apple app store
We are pleased to announce the Pill Identifier Lite mobile application has become the #1 paid medical app in the U.S. Apple App store. Thanks to all those who have downloaded the app. We look forward to providing regular updates and improvements. Please check out our apps page to get more information on our growing […]